Active Biotech AB Interim Report January-June 2008


Comments from President & CEO Sven Andréasson:
"Enrolment for another clinical Phase III study for laquinimod started during the period and complete Phase II data was published in the respected medical journal The Lancet. The planned interim analysis from the first part of the Phase II/III trial for the ANYARA cancer project presented positive data and the pivotal Phase III study commenced in May. We now have two Phase III projects and three clinical Phase II projects. Consequently, we have further strengthened Active Biotech's position as a company with a balanced and mature project portfolio."
For further information, please contact:
Sven Andréasson
President & CEO
Tel: +46 (0)46-19 20 49
Göran Forsberg
VP Communication & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam Active Biotech AB
CFO (Corp. Reg. No. 556223-9227)
Tel +46 (0)46-19 20 44 PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50
This report is also available at

pdfActive Biotech AB Interim Report Jan-June 2008